Nutranomics announces Glucozyme™ launch - Nutrac
Post# of 94282
Posted On: 11/22/2013 7:29:59 AM
Nutranomics announces Glucozyme™ launch - Nutraceutical product Glucozyme™ supports healthy blood sugar levels to be sold...
DRAPER, Utah, Nov. 22, 2013 /PRNewswire/ -- Nutranomics, Inc. (OTCBB: NNRX) (OTCQB: NNRX) ("Nutranomics" or the "Company") is pleased to announce the official commercial launch of Glucozyme™, a nutritional supplement developed by Nutranomics to assist in the reduction of blood glucose levels in patients with Type 2 diabetes. The Company will offer Glucozyme™ for sale direct to consumers and distributors through its e-commerce website at www.nutranomics.com beginning December 1st, 2013.
"Following the successful completion of three separate studies on Glucozyme™ regarding the reduction of blood sugar levels, we are very confident that this product is ready for distribution throughout the U.S. and Japanese markets," stated Dr. Tracy K. Gibbs, Nutranomics CEO. "Though legally we cannot make any medical claims regarding the treatment of disease with Glucozyme™, I strongly believe that diseases such as heart disease, diabetes, and many others are diet and lifestyle related and that high-quality dietary supplements can play an important role in providing positive outcomes for people and their families."
Three separate studies conducted on Glucozyme™ regarding the reduction of blood sugar levels were unanimously positive. The three studies measured both the fasting glucose levels and the HbA1-c levels of Type 2 diabetics for 30, 60, and 90 days. The results of each study showed that Glucozyme™ reduced blood sugar levels and HbA1-c levels in patients by 22-28% within the study period.
Dr. Gibbs concluded, "A lot of hard work and brain power from the entire Nutranomics team has gone into the development and testing of Glucozyme™, so I'm extremely pleased that it has become a potential breakthrough product for us in 2014. I look forward to discussing the Glucozyme™ study results and distribution opportunities with our current and potential new customers in the USA and particularly in Asia during the coming weeks."
According to the International Diabetes Federation (IDF), Type 2 diabetes affects more than 371 million people worldwide. For additional information regarding type 2 diabetes and pre-diabetes (IGT) visit http://www.idf.org/worlddiabetesday/toolkit/gp/facts-figures.
About Nutranomics
Nutranomics is a publicly traded company engaged in research and development of nutritional food products. In 1997, Nutranomics produced and branded its own product line, and began to sell to the retail outlets and to the public. Nutranomics has also produced formulas for hundreds of other companies. Nutranomics' mission is to increase human health and longevity through education and self-awareness. The Company has sales representatives throughout North America and Asia.
For further information regarding Nutranomics, Inc., please contact our investor relations representatives at ir@nutranomics.com or call toll-free (888) 616-3999.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements." Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, but are not limited to, the implied potential for revenue from Glucozyme sales, and distribution opportunities with and potential new customers is Asia. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products and operating as a development stage company, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by applicable law, including the securities laws of the United States. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
SOURCE Nutranomics, Inc.
Copyright 2013 PR Newswire
DRAPER, Utah, Nov. 22, 2013 /PRNewswire/ -- Nutranomics, Inc. (OTCBB: NNRX) (OTCQB: NNRX) ("Nutranomics" or the "Company") is pleased to announce the official commercial launch of Glucozyme™, a nutritional supplement developed by Nutranomics to assist in the reduction of blood glucose levels in patients with Type 2 diabetes. The Company will offer Glucozyme™ for sale direct to consumers and distributors through its e-commerce website at www.nutranomics.com beginning December 1st, 2013.
"Following the successful completion of three separate studies on Glucozyme™ regarding the reduction of blood sugar levels, we are very confident that this product is ready for distribution throughout the U.S. and Japanese markets," stated Dr. Tracy K. Gibbs, Nutranomics CEO. "Though legally we cannot make any medical claims regarding the treatment of disease with Glucozyme™, I strongly believe that diseases such as heart disease, diabetes, and many others are diet and lifestyle related and that high-quality dietary supplements can play an important role in providing positive outcomes for people and their families."
Three separate studies conducted on Glucozyme™ regarding the reduction of blood sugar levels were unanimously positive. The three studies measured both the fasting glucose levels and the HbA1-c levels of Type 2 diabetics for 30, 60, and 90 days. The results of each study showed that Glucozyme™ reduced blood sugar levels and HbA1-c levels in patients by 22-28% within the study period.
Dr. Gibbs concluded, "A lot of hard work and brain power from the entire Nutranomics team has gone into the development and testing of Glucozyme™, so I'm extremely pleased that it has become a potential breakthrough product for us in 2014. I look forward to discussing the Glucozyme™ study results and distribution opportunities with our current and potential new customers in the USA and particularly in Asia during the coming weeks."
According to the International Diabetes Federation (IDF), Type 2 diabetes affects more than 371 million people worldwide. For additional information regarding type 2 diabetes and pre-diabetes (IGT) visit http://www.idf.org/worlddiabetesday/toolkit/gp/facts-figures.
About Nutranomics
Nutranomics is a publicly traded company engaged in research and development of nutritional food products. In 1997, Nutranomics produced and branded its own product line, and began to sell to the retail outlets and to the public. Nutranomics has also produced formulas for hundreds of other companies. Nutranomics' mission is to increase human health and longevity through education and self-awareness. The Company has sales representatives throughout North America and Asia.
For further information regarding Nutranomics, Inc., please contact our investor relations representatives at ir@nutranomics.com or call toll-free (888) 616-3999.
Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements." Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, but are not limited to, the implied potential for revenue from Glucozyme sales, and distribution opportunities with and potential new customers is Asia. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products and operating as a development stage company, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by applicable law, including the securities laws of the United States. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
SOURCE Nutranomics, Inc.
Copyright 2013 PR Newswire
(0)
(0)